Moderna rebounded approximately days before the release of detailed Phase cancer therapy data 11%
Moderna will present October 24 detailed Phase data for a combination therapy for high-risk melanoma,MRNA with a cumulative gain of approximately 11%over the past trading days. The report also stated that a MRNA short position is approaching its estimated liquidation price.